Health-related quality of life in patients with recurrent infections
Background: The health-related quality of life (HrQoL) can be substantially affected in patients with recurrent Clostridioides difficile infection (rCDI) but the impact of effective treatment of the infection remains unclear. This study aimed to evaluate the HrQoL in patients with rCDI and estimate...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-02-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848221078441 |
| _version_ | 1811304065568604160 |
|---|---|
| author | Lianna H. Hammeken Simon M. D. Baunwall Jens F. Dahlerup Christian L. Hvas Lars H. Ehlers |
| author_facet | Lianna H. Hammeken Simon M. D. Baunwall Jens F. Dahlerup Christian L. Hvas Lars H. Ehlers |
| author_sort | Lianna H. Hammeken |
| collection | DOAJ |
| description | Background: The health-related quality of life (HrQoL) can be substantially affected in patients with recurrent Clostridioides difficile infection (rCDI) but the impact of effective treatment of the infection remains unclear. This study aimed to evaluate the HrQoL in patients with rCDI and estimate the gain in HrQoL associated with effective treatment of rCDI. Methods: Patients’ HrQoL was estimated based on EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) questionnaires obtained from a Danish randomised controlled trial (RCT). In the RCT, 64 patients with rCDI were randomised to receive either vancomycin ( n = 16), fidaxomicin ( n = 24) or faecal microbiota transplantation (FMT) preceded by vancomycin ( n = 24). The primary outcome in the RCT was rCDI resolution. Patients were closely monitored during the RCT, and rescue FMT was offered to those who failed their primary treatment. Patients’ HrQoL was measured at baseline and at 8- and 26-weeks follow-up. Linear regression analyses conditional on the differences between baseline and follow-up measurements were used to assess statistical significance ( p < 0.05). Results: Within 26 weeks of follow-up, 13 (81%) patients treated with vancomycin, 12 (50%) patients treated with fidaxomicin, and 3 (13%) patients treated with FMT had a subsequent recurrence and received a rescue FMT. The average HrQoL for untreated patients with rCDI was 0.675. After receiving effective treatment, this value increased by 0.139 to 0.813 ( p < 0.001) at week 8 and by 0.098 to 0.773 ( p = 0.003) at week 26 of follow-up compared with baseline. Conclusion: The HrQoL was adversely affected in patients with an active episode of rCDI but increased substantially after receiving an effective treatment algorithm in which rescue FMT was provided in case of a primary treatment failure. Trial registration: The RCT was preregistered at EudraCT (j.no. 2015-003004-24, https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003004-24/results ) and at ClinicalTrials.gov (study identifier NCT02743234, https://clinicaltrials.gov/ct2/show/NCT02743234 ). |
| first_indexed | 2024-04-13T07:59:18Z |
| format | Article |
| id | doaj.art-95df06776acc4ae9b9a9bf118656cc23 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-04-13T07:59:18Z |
| publishDate | 2022-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-95df06776acc4ae9b9a9bf118656cc232022-12-22T02:55:19ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482022-02-011510.1177/17562848221078441Health-related quality of life in patients with recurrent infectionsLianna H. HammekenSimon M. D. BaunwallJens F. DahlerupChristian L. HvasLars H. EhlersBackground: The health-related quality of life (HrQoL) can be substantially affected in patients with recurrent Clostridioides difficile infection (rCDI) but the impact of effective treatment of the infection remains unclear. This study aimed to evaluate the HrQoL in patients with rCDI and estimate the gain in HrQoL associated with effective treatment of rCDI. Methods: Patients’ HrQoL was estimated based on EuroQol 5-Dimensions 3-Levels (EQ-5D-3L) questionnaires obtained from a Danish randomised controlled trial (RCT). In the RCT, 64 patients with rCDI were randomised to receive either vancomycin ( n = 16), fidaxomicin ( n = 24) or faecal microbiota transplantation (FMT) preceded by vancomycin ( n = 24). The primary outcome in the RCT was rCDI resolution. Patients were closely monitored during the RCT, and rescue FMT was offered to those who failed their primary treatment. Patients’ HrQoL was measured at baseline and at 8- and 26-weeks follow-up. Linear regression analyses conditional on the differences between baseline and follow-up measurements were used to assess statistical significance ( p < 0.05). Results: Within 26 weeks of follow-up, 13 (81%) patients treated with vancomycin, 12 (50%) patients treated with fidaxomicin, and 3 (13%) patients treated with FMT had a subsequent recurrence and received a rescue FMT. The average HrQoL for untreated patients with rCDI was 0.675. After receiving effective treatment, this value increased by 0.139 to 0.813 ( p < 0.001) at week 8 and by 0.098 to 0.773 ( p = 0.003) at week 26 of follow-up compared with baseline. Conclusion: The HrQoL was adversely affected in patients with an active episode of rCDI but increased substantially after receiving an effective treatment algorithm in which rescue FMT was provided in case of a primary treatment failure. Trial registration: The RCT was preregistered at EudraCT (j.no. 2015-003004-24, https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003004-24/results ) and at ClinicalTrials.gov (study identifier NCT02743234, https://clinicaltrials.gov/ct2/show/NCT02743234 ).https://doi.org/10.1177/17562848221078441 |
| spellingShingle | Lianna H. Hammeken Simon M. D. Baunwall Jens F. Dahlerup Christian L. Hvas Lars H. Ehlers Health-related quality of life in patients with recurrent infections Therapeutic Advances in Gastroenterology |
| title | Health-related quality of life in patients with recurrent infections |
| title_full | Health-related quality of life in patients with recurrent infections |
| title_fullStr | Health-related quality of life in patients with recurrent infections |
| title_full_unstemmed | Health-related quality of life in patients with recurrent infections |
| title_short | Health-related quality of life in patients with recurrent infections |
| title_sort | health related quality of life in patients with recurrent infections |
| url | https://doi.org/10.1177/17562848221078441 |
| work_keys_str_mv | AT liannahhammeken healthrelatedqualityoflifeinpatientswithrecurrentinfections AT simonmdbaunwall healthrelatedqualityoflifeinpatientswithrecurrentinfections AT jensfdahlerup healthrelatedqualityoflifeinpatientswithrecurrentinfections AT christianlhvas healthrelatedqualityoflifeinpatientswithrecurrentinfections AT larshehlers healthrelatedqualityoflifeinpatientswithrecurrentinfections |